<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="hsr270849" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Health Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Health Sci Rep</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2398-8835</journal-id><journal-id journal-id-type="publisher-id">HSR2</journal-id><journal-title-group><journal-title>Health Science Reports</journal-title></journal-title-group><issn pub-type="epub">2398-8835</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098968</article-id><article-id pub-id-type="doi">10.1002/hsr2.70849</article-id><article-id pub-id-type="publisher-id">HSR270849</article-id><article-categories><subj-group subj-group-type="overline"><subject>Systematic Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Racecadotril Versus Loperamide for Acute Diarrhea of Infectious Origin in Adults: A Systematic Review and Meta&#x02010;Analysis</article-title></title-group><contrib-group><contrib id="hsr270849-cr-0001" contrib-type="author"><name><surname>Aziz</surname><given-names>Maryam</given-names></name><xref rid="hsr270849-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="hsr270849-cr-0002" contrib-type="author"><name><surname>Malik</surname><given-names>Laiba Urooj</given-names></name><xref rid="hsr270849-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hsr270849-cr-0003" contrib-type="author"><name><surname>Javed</surname><given-names>Erum</given-names></name><xref rid="hsr270849-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hsr270849-cr-0004" contrib-type="author"><name><surname>Sami</surname><given-names>Syeda Zuha</given-names></name><xref rid="hsr270849-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hsr270849-cr-0005" contrib-type="author"><name><surname>Maaz</surname><given-names>Muhammad</given-names></name><xref rid="hsr270849-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hsr270849-cr-0006" contrib-type="author"><name><surname>Khan</surname><given-names>Muhammad Arham</given-names></name><xref rid="hsr270849-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hsr270849-cr-0007" contrib-type="author"><name><surname>Farmaan</surname><given-names>Muhammad</given-names></name><xref rid="hsr270849-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hsr270849-cr-0008" contrib-type="author"><name><surname>Farooq</surname><given-names>Omer</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9604-1792</contrib-id><xref rid="hsr270849-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="hsr270849-cr-0009" contrib-type="author"><name><surname>Iqbal</surname><given-names>Umer</given-names></name><xref rid="hsr270849-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hsr270849-cr-0010" contrib-type="author"><name><surname>Kumar</surname><given-names>Aashish</given-names></name><xref rid="hsr270849-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hsr270849-cr-0011" contrib-type="author"><name><surname>Arsal</surname><given-names>Syed Ali</given-names></name><xref rid="hsr270849-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hsr270849-cr-0012" contrib-type="author"><name><surname>Amin</surname><given-names>Shafin Bin</given-names></name><xref rid="hsr270849-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="hsr270849-cr-0013" contrib-type="author" corresp="yes"><name><surname>Okon</surname><given-names>Inibehe Ime</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-8275-5713</contrib-id><xref rid="hsr270849-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><address><email>inibeheokon3@gmail.com</email></address></contrib></contrib-group><aff id="hsr270849-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Dow University of Health Sciences</institution>
<city>Karachi</city>
<country country="PK">Pakistan</country>
</aff><aff id="hsr270849-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Shaheed Mohtarma Benazir Bhutto Medical College</institution>
<city>Karachi</city>
<country country="PK">Pakistan</country>
</aff><aff id="hsr270849-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Karachi Medical and Dental College</institution>
<city>Karachi</city>
<country country="PK">Pakistan</country>
</aff><aff id="hsr270849-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine, Khyber Medical College</named-content>
<institution>University of Peshawar</institution>
<city>Peshawar</city>
<country country="PK">Pakistan</country>
</aff><aff id="hsr270849-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Jinnah Sindh Medical University</institution>
<city>Karachi</city>
<country country="PK">Pakistan</country>
</aff><aff id="hsr270849-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Research</named-content>
<institution>Medical Research Circle (MedReC)</institution>
<city>Bukavu</city>
<country country="CD">DR Congo</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold> Inibehe Ime Okon (<email>inibeheokon3@gmail.com</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>8</volume><issue seq="20">5</issue><issue-id pub-id-type="doi">10.1002/hsr2.v8.5</issue-id><elocation-id>e70849</elocation-id><history>
<date date-type="rev-recd"><day>17</day><month>4</month><year>2025</year></date>
<date date-type="received"><day>25</day><month>10</month><year>2024</year></date>
<date date-type="accepted"><day>28</day><month>4</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 The Author(s). Health Science Reports published by Wiley Periodicals LLC.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Health Science Reports</italic> published by Wiley Periodicals LLC.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:HSR2-8-e70849.pdf"/><abstract><title>ABSTRACT</title><sec id="hsr270849-sec-0010"><title>Background and Aims</title><p>Loperamide and racecadotril are two antidiarrheal medications with different mechanisms of action that are highly important for the treatment of diarrhea as a result of infectious pathology. Acute infectious diarrhea has a profound impact on our surroundings because of its detrimental effects on individual health. Medication such as racecadotril, among various other drug classes, plays a pivotal role in treating these diseases via the management of symptoms through its antisecretory, proabsorptive effects on the intestinal tract. The main objective of this analysis was to evaluate and contrast the usefulness and safety profiles of these drugs by combining information from randomized controlled trials and highlighting important side effects reported, such as constipation and stomach discomfort.</p></sec><sec id="hsr270849-sec-0020"><title>Method</title><p>A total of 117 records were found after a thorough literature search was carried out across several databases, including PubMed, Google Scholar, and the Cochrane Library. The Cochrane Collaboration technique was utilized to evaluate the potential for bias. RevMan 5.2 data analysis was performed via a random effects model. The results are displayed as the mean difference (MD) with 95% CI for continuous data and relative risk (RR) with 95% confidence intervals (CIs) for dichotomous data. Statistical significance was established at <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec><sec id="hsr270849-sec-0030"><title>Results</title><p>Compared with loperamide, racecadotril significantly improved the clinical response (relative risk [RR] and 95% confidence interval [CI]). Additionally, the analysis of secondary outcomes revealed varying effects on abdominal pain, constipation, and abdominal enlargement, with moderate heterogeneity observed (<italic toggle="yes">I</italic>&#x000b2;&#x02009;=&#x02009;56%).</p></sec><sec id="hsr270849-sec-0040"><title>Conclusion</title><p>Compared with loperamide, racecadotril is a better therapeutic option for adult diarrhea caused by infection.</p></sec></abstract><kwd-group><kwd id="hsr270849-kwd-0001">diarrhea</kwd><kwd id="hsr270849-kwd-0002">infectious origin</kwd><kwd id="hsr270849-kwd-0003">loperamide</kwd><kwd id="hsr270849-kwd-0004">meta&#x02010;analysis</kwd><kwd id="hsr270849-kwd-0005">racecadotril</kwd><kwd id="hsr270849-kwd-0006">randomized controlled trials</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>The authors received no specific funding for this work.</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="8"/><word-count count="4934"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:23.05.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="hsr270849-sec-0050"><label>1</label><title>Introduction</title><p>Diarrhea is a prevalent condition worldwide that can be characterized by a minimum frequency of three episodes per day. These episodes may be accompanied by additional symptoms such as stomach discomfort, cramping, and a feeling of urgency [<xref rid="hsr270849-bib-0001" ref-type="bibr">1</xref>]. The main etiologic factors pertaining to diarrhea can be of infectious or noninfectious origin. Bacteria, viruses, and other microorganisms lead to infectious diarrhea, while noninfectious diarrhea can have multiple causes [<xref rid="hsr270849-bib-0002" ref-type="bibr">2</xref>].</p><p>Compared with any other gastrointestinal disease, infectious diarrhea is a leading cause of death globally. Approximately 1.6 million deaths were reported in 2016 alone, making infectious diarrhea the eighth leading cause of death worldwide [<xref rid="hsr270849-bib-0003" ref-type="bibr">3</xref>]. Within the United States alone, nearly 179 million cases of diarrhea have been estimated according to the latest reports [<xref rid="hsr270849-bib-0004" ref-type="bibr">4</xref>].</p><p>Antidiarrheal drugs are differentiated on the basis of their mechanisms of action, such as reducing motility, decreasing the secretions of the intestines, and increasing the time of absorption [<xref rid="hsr270849-bib-0005" ref-type="bibr">5</xref>, <xref rid="hsr270849-bib-0006" ref-type="bibr">6</xref>]. Common antidiarrheal drugs include loperamide, diphenoxylate&#x02010;atropine, racecadotril, octreotide, clonidine, pancreatic enzymes, 5&#x02010;HT3 receptor antagonists, diosmectite, cholestyramine, probiotics, and rifaximin, among others [<xref rid="hsr270849-bib-0005" ref-type="bibr">5</xref>, <xref rid="hsr270849-bib-0006" ref-type="bibr">6</xref>, <xref rid="hsr270849-bib-0007" ref-type="bibr">7</xref>, <xref rid="hsr270849-bib-0008" ref-type="bibr">8</xref>]. The most common and frequently used drug to treat diarrhea is loperamide [<xref rid="hsr270849-bib-0006" ref-type="bibr">6</xref>].</p><p>While taking care of diarrhea, antidiarrheal drugs can also have side effects depending on their usage [<xref rid="hsr270849-bib-0009" ref-type="bibr">9</xref>]. Common symptoms of antidiarrheal medicines are severe constipation, abdominal pain, bloating, nausea, and vomiting [<xref rid="hsr270849-bib-0010" ref-type="bibr">10</xref>]. Another article reported hypotension as an adverse effect [<xref rid="hsr270849-bib-0011" ref-type="bibr">11</xref>]. Therefore, it is crucial to be aware of the potential effects while using these medications [<xref rid="hsr270849-bib-0009" ref-type="bibr">9</xref>]. Our meta&#x02010;analysis aimed to combine different studies comparing the efficacy of the antidiarrheal drugs racecadotril and loperamide. Our study also focused on different secondary outcomes of both drugs, such as abdominal pain, distention, enlargement, and constipation.</p></sec><sec sec-type="methods" id="hsr270849-sec-0060"><label>2</label><title>Methodology</title><sec id="hsr270849-sec-0070"><label>2.1</label><title>Eligibility Criteria</title><p>Only randomized controlled trials were included in this meta&#x02010;analysis. They looked at the effects of loperamide and racecadotril on patients with an infectious source of diarrhea. The meta&#x02010;analysis included only RCTs that focused on acute infectious diarrhea, defined as diarrhea lasting less than 14 days. This ensured that the analysis excluded chronic forms of diarrhea, which can persist longer than 14 days. RCTs whose intervention group was administered racecadotril were selected, whereas the control group used loperamide among those who had diarrhea from infections. The research involved adult patients, ranging in age from young adults to the elderly. Separate analyses of pediatric populations were not performed, as all the included studies involved adult participants aged 18 years and older till 96 years. Qualitative articles, nonhuman studies, letters to editors/experts, and abstracts presented by conferences were not considered for analysis because they did not address the study question directly or provide data that could be retrieved for this review. After all, such studies lack a comparison group for comparison with other forms of reviews written in English. Furthermore, strict adherence to RCTs was done to evade any biases in the meta&#x02010;analysis, as well as ensuring a consistent analytical approach was carried out for all studies. Even though the concept of other study types could bring enhancement from a singular point of view, using RCTs specifically calibrates more the preciseness of the meta&#x02010;analysis by distributing confounding variables equally through randomization, as well as providing a controlled environment to better engage the direct assessment of the treatment groups throughout the study and thus only studies following the randomized clinical trial design were accepted.</p></sec><sec id="hsr270849-sec-0080"><label>2.2</label><title>Literature Search and Search Strategy</title><p>A thorough search strategy was developed using keywords such as &#x0201c;racecadotril&#x0201d; OR &#x0201c;enkephalinase,&#x0201d; &#x0201c;loperamide&#x0201d; OR &#x0201c;antidiarrheal,&#x0201d; and &#x0201c;acute diarrhea&#x0201d; because our focus was on finding information. We looked for original research comparing loperamide with racecadotril in patients with infectious diarrhea by searching electronic databases such as PubMed, Cochrane, and Google Scholar. These keywords produced 117 results. Furthermore, a manual search was conducted through the reference lists of the included articles to identify other relevant studies. Conversely, this study was not limited to any linguistic factors. This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta&#x02010;Analyses (PRISMA) guidelines, which ensure transparency and accuracy in the review process, and its protocol is registered with PROSPERO.</p></sec><sec id="hsr270849-sec-0090"><label>2.3</label><title>Study Selection</title><p>The first step in the study selection process was identifying possibly relevant studies by analyzing the titles and abstracts of the accumulated data. Following a study of the selected articles' entire texts, two researchers assessed each to decide whether they might include it in the meta&#x02010;analysis. Studies comparing the efficacy of loperamide with that of racecadotril in treating individuals with infectious diarrhea, particularly in the adult population, have been conducted. Excluded studies included racecadotril and loperamide in combination with other medications or placebos. When differences surfaced, discussions with a third researcher were held to reach an agreement. To improve transparency in the review process, the PRISMA flowchart (Figure&#x000a0;<xref rid="hsr270849-fig-0002" ref-type="fig">2</xref>) was used to demonstrate the research selection process and the justifications for omitting studies. This comprehensive approach uses an unbiased and thorough methodology.</p></sec><sec id="hsr270849-sec-0100"><label>2.4</label><title>Data Extraction</title><p>The data extraction process was independently conducted by two investigators to ensure accuracy, with a subsequent review by a third investigator for validation. Our analysis included baseline information, intervention details, patient numbers, dichotomous data, and continuous data from the selected randomized controlled trials (RCTs) as well as from other RCTs. The study's primary outcome was the clinical response of each treatment group, being the time from the first dose of treatment to the resolution of diarrhea or the production of the first formed stool. Both sets of data were dichotomous. Constipation, abdominal enlargement/distension, and abdominal pain were among the secondary outcomes. These outcomes are analyzed via odds ratios. The study title, publication year, primary author's name, study year, country of origin, participant count, type of intervention used, and outcome measures assessed were all recorded in this comprehensive data collection form. Furthermore, the form included detailed trial characteristics, including author details, country of origin, DOI, journal, year of publication, type of study, age in the intervention group, age in the placebo group, number of participants in the intervention group, number of participants in the placebo group, and gender distribution (percentage of males) in both groups.</p></sec><sec id="hsr270849-sec-0110"><label>2.5</label><title>Risk of Bias Assessment</title><p>To formally evaluate the quality of the selected studies, two authors were chosen, and they used the Cochrane Collaboration method for assessing the risk of bias in randomized studies. Essential factors such as participant blinding, random sequence generation, outcome assessment, incomplete outcome data, and more potential causes of bias were taken into consideration when evaluating bias. On the basis of their assessment, the studies were categorized into three groups: unclear risk of bias due to incomplete data, high risk of bias, and low risk of bias. When there were differences, a third researcher was involved in the discussions to obtain a consensus. The risk of bias summary and graphical assessment is detailed in Figure&#x000a0;<xref rid="hsr270849-fig-0001" ref-type="fig">1</xref> and see Supporting Information S1: Figure&#x000a0;<xref rid="hsr270849-suppl-0001" ref-type="supplementary-material">S1</xref> respectively.</p><fig position="float" fig-type="Figure" id="hsr270849-fig-0001"><label>Figure 1</label><caption><p>Risk of bias summary: Review authors' judgments about every risk of bias item for each included study.</p></caption><graphic xlink:href="HSR2-8-e70849-g002" position="anchor" id="jats-graphic-1"/></fig></sec></sec><sec id="hsr270849-sec-0120"><label>3</label><title>Statistical Analysis</title><p>The data analysis was performed via RevMan 5.2 (Review Manager, version 5.2). A random&#x02010;effects model was used to determine the outcomes of interest in this meta&#x02010;analysis. For dichotomous data, findings are presented as the relative risk (RR) (define as; a measure of the risk of a certain event happening in one group compared to the risk of the same event happening in another group.) and 95% confidence interval (CI) (define as; a range of values that you can be 95% certain contains the true mean of the population). For continuous data, we used the mean difference (MD) (defined as a statistical measurement that compares the average values of two groups) and corresponding 95% CI(s). A <italic toggle="yes">p</italic> value&#x02009;&#x0003c;&#x02009;0.05 was considered a statistically significant result; statistical heterogeneity was visually evaluated via a forest plot via the <italic toggle="yes">&#x003c7;</italic>
<sup>2</sup> test (define as; a statistical test used to compare observed results with expected results) and <italic toggle="yes">I</italic>
<sup>2</sup> test (define as; a statistical measure used in meta&#x02010;analyses to assess study heterogeneity, or the amount of variation between studies). Heterogeneity was considered high when the <italic toggle="yes">p</italic> value was &#x0003c;&#x02009;0.5 or <italic toggle="yes">I</italic>
<sup>2</sup>&#x02009;&#x0003e;&#x02009;50%, in which case a leave&#x02010;one&#x02010;out analysis was performed to exclude the cause, if any.</p></sec><sec sec-type="results" id="hsr270849-sec-0130"><label>4</label><title>Results</title><sec id="hsr270849-sec-0140"><label>4.1</label><title>Search and Selection Process</title><p>In our meta&#x02010;analysis of five RCTs, we adhered to the PRISMA guidelines. Initially, we identified 117 records from PubMed (56), Google Scholar (42), and the Cochrane Library (19). After 21 duplicate records were removed, 96 records were screened, resulting in the exclusion of 24 records on the basis of title. We sought to retrieve 72 reports for full&#x02010;text assessment, of which 42 reports were not retrieved due to their inaccessibility pertaining upon trial by multiple authors even on multiple occasions throughout the study, in dire efforts to retrieve them, yet still led to failure; hence, 30 reports were assessed for eligibility. Ten reports were excluded after the abstracts were read, five were excluded because of the unavailability of full texts or abstracts, and eight were excluded because they were not in English. Any incongruities or discrepancies in judgments were resolved through discussion and agreement between the two authors. In addition, the reference lists of the included studies were also searched manually to extract any significant studies possibly missed during the initial search. Finally, five [<xref rid="hsr270849-bib-0012" ref-type="bibr">12</xref>, <xref rid="hsr270849-bib-0013" ref-type="bibr">13</xref>, <xref rid="hsr270849-bib-0014" ref-type="bibr">14</xref>, <xref rid="hsr270849-bib-0015" ref-type="bibr">15</xref>, <xref rid="hsr270849-bib-0016" ref-type="bibr">16</xref>] studies satisfying the inclusion criteria were included in our meta&#x02010;analysis. The PRISMA flowchart below summarizes our screening process (Figure&#x000a0;<xref rid="hsr270849-fig-0002" ref-type="fig">2</xref>).</p><fig position="float" fig-type="Figure" id="hsr270849-fig-0002"><label>Figure 2</label><caption><p>PRISMA flow chart.</p></caption><graphic xlink:href="HSR2-8-e70849-g003" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="hsr270849-sec-0150"><label>4.2</label><title>Study Characteristics</title><p>The comprehensive baseline characteristics of the studies included in our meta&#x02010;analysis can be reviewed in Table&#x000a0;<xref rid="hsr270849-tbl-0001" ref-type="table">1</xref>, which shows the effects of racecadotril compared with loperamide in patients with diarrhea of infectious origin. Details about the country, design of the study, interventional group, control group, patient characteristics and outcomes of the selected studies are also reported. Our sample included males and females whose mean age in the intervention group was between 36 and 90 years, and that in the placebo group was between 35 and 93 years. A total of five studies [<xref rid="hsr270849-bib-0012" ref-type="bibr">12</xref>, <xref rid="hsr270849-bib-0013" ref-type="bibr">13</xref>, <xref rid="hsr270849-bib-0014" ref-type="bibr">14</xref>, <xref rid="hsr270849-bib-0015" ref-type="bibr">15</xref>, <xref rid="hsr270849-bib-0016" ref-type="bibr">16</xref>] consisting of 1294 participants, comprising males and females in the intervention and placebo groups, were included. It is of note that only Gallelli et al. [<xref rid="hsr270849-bib-0013" ref-type="bibr">13</xref>] performed stool cultures, confirming the absence of bacterial pathogens in the study population and other studies, such as Prado [<xref rid="hsr270849-bib-0016" ref-type="bibr">16</xref>] and Vetel et al. [<xref rid="hsr270849-bib-0015" ref-type="bibr">15</xref>], presumed an infectious etiology but did not perform stool cultures. All the studies reported diarrhea of watery type. Our study included participants with different outcomes, and the data were analyzed via RevMan.</p><table-wrap position="float" id="hsr270849-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Characteristics of the included studies.</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="left" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><thead valign="bottom"><tr valign="bottom"><th align="left" colspan="15" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Study characteristics</th></tr><tr valign="bottom" style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1">Article no.</th><th rowspan="2" align="center" valign="bottom" colspan="1">Author</th><th rowspan="2" align="center" valign="bottom" colspan="1">Year</th><th rowspan="2" align="center" valign="bottom" colspan="1">Type of study</th><th rowspan="2" align="center" valign="bottom" colspan="1">Country</th><th colspan="2" align="center" valign="bottom" rowspan="1">Sample size</th><th colspan="2" align="center" valign="bottom" rowspan="1">Age</th><th colspan="2" align="center" valign="bottom" rowspan="1">Gender (<italic toggle="yes">M</italic>%)</th><th rowspan="2" align="center" valign="bottom" colspan="1">Duration of diarrhea before treatment</th><th rowspan="2" align="center" valign="bottom" colspan="1">Type of diarrhea</th><th rowspan="2" align="center" valign="bottom" colspan="1">Stool cultures</th><th rowspan="2" align="center" valign="bottom" colspan="1">Infectious etiology</th></tr><tr valign="bottom" style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Racecadotril</th><th align="center" valign="bottom" rowspan="1" colspan="1">Loperamide</th><th align="center" valign="bottom" rowspan="1" colspan="1">Racecadotril</th><th align="center" valign="bottom" rowspan="1" colspan="1">Loperamide</th><th align="center" valign="bottom" rowspan="1" colspan="1">Racecadotril</th><th align="center" valign="bottom" rowspan="1" colspan="1">Loperamide</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">Wang [<xref rid="hsr270849-bib-0012" ref-type="bibr">12</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">2005</td><td align="center" valign="top" rowspan="1" colspan="1">Two&#x02010;center, randomized, parallel&#x02010;group, single&#x02010;blind study.</td><td align="center" valign="top" rowspan="1" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="center" valign="top" rowspan="1" colspan="1">38.4&#x02009;&#x000b1;&#x02009;15.1</td><td align="center" valign="top" rowspan="1" colspan="1">34.7&#x02009;&#x000b1;&#x02009;12.3</td><td align="center" valign="top" rowspan="1" colspan="1">48.4</td><td align="center" valign="top" rowspan="1" colspan="1">54.8</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;5 days</td><td align="center" valign="top" rowspan="1" colspan="1">Watery diarrhea</td><td align="center" valign="top" rowspan="1" colspan="1">Not performed</td><td align="center" valign="top" rowspan="1" colspan="1">Presumed infectious</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">Gallelli et al. [<xref rid="hsr270849-bib-0013" ref-type="bibr">13</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">2009</td><td align="center" valign="top" rowspan="1" colspan="1">Prospective, randomized, double&#x02010;blind trial.</td><td align="center" valign="top" rowspan="1" colspan="1">Italy</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="center" valign="top" rowspan="1" colspan="1">83.9&#x02009;&#x000b1;&#x02009;17</td><td align="center" valign="top" rowspan="1" colspan="1">82.6&#x02009;&#x000b1;&#x02009;14.8</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">32.26</td><td align="center" valign="top" rowspan="1" colspan="1">Not reported</td><td align="center" valign="top" rowspan="1" colspan="1">Watery diarrhea</td><td align="center" valign="top" rowspan="1" colspan="1">Performed</td><td align="center" valign="top" rowspan="1" colspan="1">Nonbacterial (negative cultures)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">Roge et al. [<xref rid="hsr270849-bib-0014" ref-type="bibr">14</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">1993</td><td align="center" valign="top" rowspan="1" colspan="1">Double&#x02010;blind, controlled clinical trial</td><td align="center" valign="top" rowspan="1" colspan="1">France</td><td align="center" valign="top" rowspan="1" colspan="1">37</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="center" valign="top" rowspan="1" colspan="1">40.8&#x02009;&#x000b1;&#x02009;2.9</td><td align="center" valign="top" rowspan="1" colspan="1">44.2&#x02009;&#x000b1;&#x02009;3.3</td><td align="center" valign="top" rowspan="1" colspan="1">44.4</td><td align="center" valign="top" rowspan="1" colspan="1">41.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;5 days</td><td align="center" valign="top" rowspan="1" colspan="1">Watery diarrhea</td><td align="center" valign="top" rowspan="1" colspan="1">Not performed</td><td align="center" valign="top" rowspan="1" colspan="1">Presumed infectious</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">Vettel et al. [<xref rid="hsr270849-bib-0015" ref-type="bibr">15</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">2003</td><td align="center" valign="top" rowspan="1" colspan="1">Randomized, double&#x02010;blind, double&#x02010;placebo, parallel&#x02010;group study</td><td align="center" valign="top" rowspan="1" colspan="1">France</td><td align="center" valign="top" rowspan="1" colspan="1">82</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">40.9&#x02009;+&#x02009;1.8</td><td align="center" valign="top" rowspan="1" colspan="1">41.5&#x02009;+&#x02009;2.2</td><td align="center" valign="top" rowspan="1" colspan="1">33</td><td align="center" valign="top" rowspan="1" colspan="1">33</td><td align="center" valign="top" rowspan="1" colspan="1">Not reported</td><td align="center" valign="top" rowspan="1" colspan="1">Watery diarrhea</td><td align="center" valign="top" rowspan="1" colspan="1">Not performed</td><td align="center" valign="top" rowspan="1" colspan="1">Presumed bacterial</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">Prado [<xref rid="hsr270849-bib-0016" ref-type="bibr">16</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">2002</td><td align="center" valign="top" rowspan="1" colspan="1">Single&#x02010;blind, randomized, comparative, parallel&#x02010;group, multinational, multicenter study</td><td align="center" valign="top" rowspan="1" colspan="1">Guatemala</td><td align="center" valign="top" rowspan="1" colspan="1">473</td><td align="center" valign="top" rowspan="1" colspan="1">472</td><td align="center" valign="top" rowspan="1" colspan="1">35.9&#x02009;&#x000b1;&#x02009;12.1</td><td align="center" valign="top" rowspan="1" colspan="1">36.4&#x02009;&#x000b1;&#x02009;13.5</td><td align="center" valign="top" rowspan="1" colspan="1">57</td><td align="center" valign="top" rowspan="1" colspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1">2.1 days</td><td align="center" valign="top" rowspan="1" colspan="1">Watery diarrhea</td><td align="center" valign="top" rowspan="1" colspan="1">Not performed</td><td align="center" valign="top" rowspan="1" colspan="1">Presumed bacterial</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><sec id="hsr270849-sec-0160"><label>4.2.1</label><title>Analysis of Outcomes</title><p>According to our PICO criteria, the outcomes of our study were the effects of racecadotril compared with loperamide in patients with diarrhea of infectious origin. However not all studies could be included for every outcome as they came short of providing data appropriate enough to warrant them included in those outcomes, this arose from inconsistencies in the type of outcomes reported throughout each study.</p></sec><sec id="hsr270849-sec-0170"><label>4.2.2</label><title>Primary Outcomes</title><sec id="hsr270849-sec-0180"><label>4.2.2.1</label><title>Treatment Response by Clinical Group</title><p>During the meta&#x02010;analysis of our study, we analyzed three studies [<xref rid="hsr270849-bib-0012" ref-type="bibr">12</xref>, <xref rid="hsr270849-bib-0014" ref-type="bibr">14</xref>, <xref rid="hsr270849-bib-0016" ref-type="bibr">16</xref>] to evaluate the possibility of a clinical response. The overall pooled effect of analysis of three studies showed an odds ratio of 0.80 [95% CI (0.47, 1.37), <italic toggle="yes">&#x003c7;</italic>
<sup>2</sup>&#x02009;=&#x02009;2.24, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.41, <italic toggle="yes">I</italic>
<sup>2</sup>&#x02009;=&#x02009;11%], explaining the nonsignificant results, as shown by a <italic toggle="yes">Z</italic> value of 0.82 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.41), indicating that the racecadotril group responded more strongly to treatment than did the loperamide group. Moreover, low heterogeneity was also observed, which refers to variation in the study outcomes between studies. For publication bias, a funnel plot (see Supporting Information S1: Figure&#x000a0;<xref rid="hsr270849-suppl-0001" ref-type="supplementary-material">S2</xref>) can be constructed, which is symmetrical and predicts low chances of bias. Figure&#x000a0;<xref rid="hsr270849-fig-0003" ref-type="fig">3</xref> shows the forest plot, which explains the OR and 95% CI for the effect of racecadotril versus loperamide.</p><fig position="float" fig-type="Figure" id="hsr270849-fig-0003"><label>Figure 3</label><caption><p>Forest plot of the clinical response to racecadotril vs. loperamide.</p></caption><graphic xlink:href="HSR2-8-e70849-g001" position="anchor" id="jats-graphic-5"/></fig></sec></sec><sec id="hsr270849-sec-0190"><label>4.2.3</label><title>Secondary Outcomes</title><sec id="hsr270849-sec-0200"><label>4.2.3.1</label><title>Constipation</title><p>During the meta&#x02010;analysis of our study, we analyzed four studies [<xref rid="hsr270849-bib-0012" ref-type="bibr">12</xref>, <xref rid="hsr270849-bib-0013" ref-type="bibr">13</xref>, <xref rid="hsr270849-bib-0014" ref-type="bibr">14</xref>, <xref rid="hsr270849-bib-0016" ref-type="bibr">16</xref>] to analyze the occurrence of therapy emergent constipation. The overall pooled effect analysis of the four studies revealed an odds ratio of 0.21 [95% CI (0. 13, 0.33), <italic toggle="yes">&#x003c7;</italic>
<sup>2</sup>&#x02009;=&#x02009;0.99, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, <italic toggle="yes">I</italic>
<sup>2</sup>&#x02009;=&#x02009;0%], revealing significant results, as shown by a <italic toggle="yes">Z</italic> value of 8.60 (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001), indicating that the racecadotril group had a lower incidence of therapy emergent constipation than the loperamide group did. For publication bias, a funnel plot (see Supporting Information S1: Figure&#x000a0;<xref rid="hsr270849-suppl-0001" ref-type="supplementary-material">S3&#x02010;A</xref>) was constructed, which was symmetrical and predicted moderate chances of bias. Supporting Information S1: Figure&#x000a0;<xref rid="hsr270849-suppl-0001" ref-type="supplementary-material">S3&#x02010;B</xref> shows the forest plot, which explains the OR and its 95% CI regarding the effect of racecadotril versus loperamide.</p></sec><sec id="hsr270849-sec-0210"><label>4.2.3.2</label><title>Abdominal Pain</title><p>For the meta&#x02010;analysis of our study, we analyzed two studies [<xref rid="hsr270849-bib-0012" ref-type="bibr">12</xref>, <xref rid="hsr270849-bib-0016" ref-type="bibr">16</xref>] to assess the incidence of abdominal pain. The overall pooled effect of the two studies yielded an odds ratio of 0.37 [95% CI (0.02, 6.43), <italic toggle="yes">&#x003c7;</italic>
<sup>2</sup>&#x02009;=&#x02009;2.30, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.49, <italic toggle="yes">I</italic>
<sup>2</sup>&#x02009;=&#x02009;56%], indicating that the results were nonsignificant and that the racecadotril group was more likely than the loperamide group to experience abdominal pain in their patients. Additionally, the heterogeneity test performed regarding the variation in study outcomes between studies revealed (<italic toggle="yes">&#x003c7;</italic>
<sup>2</sup>&#x02009;=&#x02009;2.30, df&#x02009;=&#x02009;1, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.13), indicating high heterogeneity (<italic toggle="yes">I</italic>
<sup>2</sup>&#x02009;=&#x02009;56%). However, owing to high heterogeneity, we could not perform sensitivity analysis to assess the risk of bias by the leave&#x02010;one&#x02010;out method because few studies have reported the incidence of abdominal pain, which could introduce bias in the results. For publication bias, a funnel plot (see Supporting Information S1: Figure&#x000a0;<xref rid="hsr270849-suppl-0001" ref-type="supplementary-material">S4&#x02010;A</xref>) was constructed, which was symmetrical and predicted moderate chances of bias. Supporting Information S1: Figure&#x000a0;<xref rid="hsr270849-suppl-0001" ref-type="supplementary-material">S4&#x02010;B</xref> shows the forest plot, which explains the OR and its 95% CI regarding the effect of racecadotril versus loperamide.</p></sec><sec id="hsr270849-sec-0220"><label>4.2.3.3</label><title>Enlarged Abdomen</title><p>In the meta&#x02010;analysis of our study, we analyzed two studies [<xref rid="hsr270849-bib-0015" ref-type="bibr">15</xref>, <xref rid="hsr270849-bib-0016" ref-type="bibr">16</xref>] to assess the occurrence of abdominal enlargement. The overall pooled effect of analysis of three studies presented an odds ratio of 0.53 [95% CI (0.13, 2.16), <italic toggle="yes">&#x003c7;</italic>
<sup>2</sup>&#x02009;=&#x02009;6.17, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.38, <italic toggle="yes">I</italic>
<sup>2</sup>&#x02009;=&#x02009;84%], presenting nonsignificant results, indicating that racecadotril group showed a beneficial response as compared to the loperamide group. Additionally, the heterogeneity test performed regarding the variation in study outcomes between studies (<italic toggle="yes">&#x003c7;</italic>
<sup>2</sup>&#x02009;=&#x02009;6.17, df&#x02009;=&#x02009;1, and <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01) revealed high heterogeneity (<italic toggle="yes">I</italic>
<sup>2</sup>&#x02009;=&#x02009;84%), but sensitivity analysis could not be performed due to insufficient studies showing abdominal enlargement. For publication bias, a funnel plot (see Supporting Information S1: Figure&#x000a0;<xref rid="hsr270849-suppl-0001" ref-type="supplementary-material">S5&#x02010;A</xref>) was generated. Supporting Information S1: Figure&#x000a0;<xref rid="hsr270849-suppl-0001" ref-type="supplementary-material">S5&#x02010;B</xref> shows the forest plot, which explains the OR and its 95% CI regarding the effect of racecadotril versus loperamide.</p></sec></sec></sec></sec><sec sec-type="discussion" id="hsr270849-sec-0230"><label>5</label><title>Discussion</title><p>Two oral medications, racecadotril and loperamide, were compared through this meta&#x02010;analysis to analyze the safety and effectiveness of their use in treating acute diarrhea of infectious pathology in the adult population. Racecadotril, also known as acetorphan, functions as an antisecretory agent in the gastrointestinal wall. Its impact is produced by blocking the enzyme enkephalinase located on the lining of the intestines. Through the lysis of enkephalin, this enzyme decreases the absorption of gut contents, resulting in increased secretions. Thus, the effects of racecadotril occur through the inhibition of the enzyme enkephalinase, which prevents the breakdown of Enkephalin and increases the absorption of the gut contents, aiding in the treatment of diarrhea [<xref rid="hsr270849-bib-0017" ref-type="bibr">17</xref>].</p><p>Loperamide, which is sold commonly under the trade name &#x0201c;Imodium&#x0201d;, has a slightly different mechanism to decrease the frequency of diarrheal episodes. It binds to the mu&#x02010;opioid receptor in the gut wall. Through this interaction, it decreases gut movements and allows increased absorption of fluid and electrolytes through the intestinal passage, thus reducing stool frequency [<xref rid="hsr270849-bib-0018" ref-type="bibr">18</xref>].</p><p>Several studies have been conducted, highlighting the contrasting features between racecadotril and loperamide, despite being an alternative treatment for the same pathologic condition. A significant number of trials have also been conducted to evaluate individual responses to these medications alongside adverse effects, including nausea, vomiting, abdominal discomfort, and any additional undesired reactions. Clinical studies have shown that racecadotril does not have a significant effect on gut motility. This mechanism can be particularly helpful when treating an infectious diarrheal condition, as normal gut movements are required to eradicate the pathogen. On the other hand, loperamide works by increasing the bulk of the stool and reducing the frequency and volume of diarrhea. Although these effects are useful, through their ability to reduce gut motility, several adverse events, such as therapy emergent constipation or toxic megacolon in complicated cases, have also been reported [<xref rid="hsr270849-bib-0019" ref-type="bibr">19</xref>].</p><p>A study conducted for the effects of racecadotril highlighted that while both medications can effectively reduce the frequency of diarrheal episodes, racecadotril has a significant advantage in that it does not affect normal bowel function [<xref rid="hsr270849-bib-0020" ref-type="bibr">20</xref>]. Multiple studies have shown that the side effects associated with racecadotril, such as nausea, vomiting, and abdominal pain, are mild compared with the severe adverse events reported with the use of loperamide [<xref rid="hsr270849-bib-0021" ref-type="bibr">21</xref>, <xref rid="hsr270849-bib-0022" ref-type="bibr">22</xref>]. However, it is of note that in the study by Prado [<xref rid="hsr270849-bib-0016" ref-type="bibr">16</xref>], racecadotril resolved the symptoms of acute diarrhea rapidly and effectively and produced more rapid resolution of abdominal symptoms and less constipation than loperamide. Also of mention should be the findings of Wang [<xref rid="hsr270849-bib-0012" ref-type="bibr">12</xref>] as these two different medications show similar adverse events such as constipation, bloody stool, abdominal pain, skin itching, palpitation, dizziness, cold sweating, and headache. Racecadotril shows further benefits in terms of clinical response, such as a reduced incidence of therapy&#x02010;emergent constipation, decreased stool volume within a day of treatment onset, and a rapid reduction in abdominal distention and the severity of symptoms [<xref rid="hsr270849-bib-0014" ref-type="bibr">14</xref>, <xref rid="hsr270849-bib-0023" ref-type="bibr">23</xref>]. The meta&#x02010;analysis specifically focused on adult populations to ensure homogeneity and relevance of the findings, as the included RCTs enrolled participants aged 18&#x02013;96 years. Concerning another aspect of the results found in the conducted meta&#x02010;analysis another noteworthy point should be the age differences in the adult population which ranged from very young adults to older individuals and even though these age&#x02010;related differences in response to treatments may exist, stratified analyses within the included studies allow for insights into the efficacy and safety of racecadotril and loperamide across younger and older adult subsets. Notably, the elderly population often presents with distinct physiological characteristics, such as altered gut motility and comorbid conditions, which could influence drug efficacy and safety profiles. While a study [<xref rid="hsr270849-bib-0013" ref-type="bibr">13</xref>] highlighted these distinctions, the clinical response trends observed across studies were consistent, supporting the generalizability of findings within the adult cohort. Future research with larger, age&#x02010;specific subgroups may provide further clarity, but for the purposes of this analysis, the inclusion of adult patients from diverse age ranges ensures robust and clinically meaningful conclusions. Overall, racecadotril has shown better tolerability than loperamide does and may be regarded as a better treatment plan for patients at risk of side effects [<xref rid="hsr270849-bib-0024" ref-type="bibr">24</xref>, <xref rid="hsr270849-bib-0025" ref-type="bibr">25</xref>].</p></sec><sec id="hsr270849-sec-0240"><label>6</label><title>Limitations and Publication Bias</title><p>Notably, some limitations existed in our meta&#x02010;analysis, including the limited number of studies we found for a few outcomes, including abdominal pain and enlargement, which impeded the ability to perform a sensitivity analysis and increased the risk of bias. Despite this data, the funnel plots generated for publication bias seem symmetrical, indicating that publication bias seems unlikely to have a profound effect on our findings.</p></sec><sec sec-type="conclusions" id="hsr270849-sec-0250"><label>7</label><title>Conclusion</title><p>In conclusion, although both racecadotril and loperamide showed comparable efficacy in terms of our primary outcomes of clinical response, racecadotril was associated with a more significant improvement in the reduction of therapy&#x02010;emergent constipation. However, these patients might have an increased risk of abdominal pain and enlargement, although the findings were insufficient for a definitive presentation. Clinicians should weigh these results according to individual patient profiles when treating patients with acute diarrhea of infectious origin. Further studies with larger sample sizes and more consistent findings are needed to confirm and weigh the advantages and disadvantages of these treatments on the observed outcomes.</p></sec><sec id="hsr270849-sec-0260"><title>Author Contributions</title><p>
<bold>Maryam Aziz:</bold> conceptualization, methodology, data curation, investigation, validation, writing &#x02013; original draft, writing &#x02013; review and editing, project administration, supervision, resources, formal analysis. <bold>Laiba Urooj Malik:</bold> conceptualization, investigation, methodology, validation, writing &#x02013; original draft, writing &#x02013; review and editing, formal analysis, project administration, data curation, resources. <bold>Erum Javed:</bold> conceptualization, investigation, methodology, validation, writing &#x02013; original draft, writing &#x02013; review and editing, formal analysis, project administration, resources, data curation. <bold>Syeda Zuha Sami:</bold> conceptualization, investigation, writing &#x02013; original draft, writing &#x02013; review and editing, validation, methodology, formal analysis, project administration, data curation, resources. <bold>Muhammad Maaz:</bold> conceptualization, investigation, writing &#x02013; original draft, methodology, validation, writing &#x02013; review and editing, formal analysis, project administration, data curation, resources. <bold>Muhammad Arham Khan:</bold> conceptualization, investigation, writing &#x02013; original draft, methodology, validation, writing &#x02013; review and editing, formal analysis, project administration, data curation, resources. <bold>Muhammad Farmaan:</bold> conceptualization, investigation, writing &#x02013; original draft, methodology, validation, writing &#x02013; review and editing, formal analysis, project administration, data curation, resources. <bold>Omer Farooq:</bold> conceptualization, investigation, writing &#x02013; original draft, methodology, validation, writing &#x02013; review and editing, formal analysis, project administration, data curation, resources. <bold>Umer Iqbal:</bold> conceptualization, investigation, writing &#x02013; original draft, writing &#x02013; review and editing, methodology, validation, formal analysis, project administration, data curation, resources, supervision. <bold>Aashish Kumar:</bold> conceptualization, investigation, writing &#x02013; original draft, methodology, validation, writing &#x02013; review and editing, formal analysis, project administration, data curation, resources. <bold>Syed Ali Arsal:</bold> conceptualization, investigation, writing &#x02013; original draft, writing &#x02013; review and editing, methodology, validation, formal analysis, project administration, data curation, resources. <bold>Shafin Bin Amin:</bold> conceptualization, investigation, writing &#x02013; original draft, methodology, validation, writing &#x02013; review and editing, formal analysis, project administration, data curation, resources. <bold>Inibehe Ime Okon:</bold> investigation, funding acquisition, writing &#x02013; review and editing, supervision.</p></sec><sec id="hsr270849-sec-0280"><title>Ethics Statement</title><p>The authors have nothing to report.</p></sec><sec id="hsr270849-sec-0290"><title>Consent</title><p>The authors have nothing to report.</p></sec><sec sec-type="COI-statement" id="hsr270849-sec-0300"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="hsr270849-sec-0330"><title>Transparency Statement</title><p>The corresponding author Inibehe Ime Okon affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="hsr270849-suppl-0001" position="float" content-type="local-data"><caption><p>For review and publication.</p></caption><media xlink:href="HSR2-8-e70849-s001.docx"/></supplementary-material></sec></body><back><ack id="hsr270849-sec-0270"><title>Acknowledgments</title><p>All authors have read and approved the final version of the manuscript. Inibehe Ime Okon had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis.</p></ack><sec sec-type="data-availability" id="hsr270849-sec-0320"><title>Data Availability Statement</title><p>The authors have nothing to report.</p></sec><ref-list content-type="cited-references" id="hsr270849-bibl-0001"><title>References</title><ref id="hsr270849-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="hsr270849-cit-0001">
<collab collab-type="authors">World Health Organization</collab>
, &#x0201c;Diarrheal Disease,&#x0201d; World Health Organization, published 2024, <ext-link xlink:href="https://www.who.int/en/news-room/fact-sheets/detail/diarrhoeal-disease" ext-link-type="uri">https://www.who.int/en/news-room/fact-sheets/detail/diarrhoeal-disease</ext-link>.</mixed-citation></ref><ref id="hsr270849-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="hsr270849-cit-0002">
<string-name>
<given-names>E. S.</given-names>
<surname>Meisenheimer</surname>,</string-name>
<string-name>
<given-names>C. D.</given-names>
<surname>Epstein</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Thiel</surname>,</string-name> &#x0201c;<article-title>Acute Diarrhea in Adults</article-title>,&#x0201d; <source>American Family Physician</source>
<volume>106</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>72</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">35839362</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="hsr270849-cit-0003">
<string-name>
<given-names>V.</given-names>
<surname>Siciliano</surname>
</string-name>, <string-name>
<given-names>E. C.</given-names>
<surname>Nista</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Ros&#x000e0;</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Brigida</surname>
</string-name>, and <string-name>
<given-names>F.</given-names>
<surname>Franceschi</surname>
</string-name>, &#x0201c;<article-title>Clinical Management of Infectious Diarrhea</article-title>,&#x0201d; <source>Reviews on Recent Clinical Trials</source>
<volume>15</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>298</fpage>&#x02013;<lpage>308</lpage>.</mixed-citation></ref><ref id="hsr270849-bib-0004"><label>4</label><mixed-citation publication-type="miscellaneous" id="hsr270849-cit-0004">&#x0201c;Definition &#x00026; Facts for Diarrhea,&#x0201d; National Institute of Diabetes and Digestive and Kidney Diseases, <ext-link xlink:href="https://www.niddk.nih.gov/health-information/digestive-diseases/diarrhea/definition-facts" ext-link-type="uri">https://www.niddk.nih.gov/health-information/digestive-diseases/diarrhea/definition-facts</ext-link>.</mixed-citation></ref><ref id="hsr270849-bib-0005"><label>5</label><mixed-citation publication-type="book" id="hsr270849-cit-0005">
<string-name>
<given-names>B.</given-names>
<surname>Maharani</surname>
</string-name>, &#x0201c;<part-title>Screening Methods for the Evaluation of Antidiarrheal Drugs</part-title>.&#x0201d; In <source>Introduction to Basics of Pharmacology and Toxicology: Volume 3: Experimental Pharmacology: Research Methodology and Biostatistics</source>, eds. <person-group person-group-type="editor">
<string-name>
<given-names>M.</given-names>
<surname>Lakshmanan</surname>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<given-names>D. G.</given-names>
<surname>Shewade</surname>
</string-name>
</person-group>, and <person-group person-group-type="editor">
<string-name>
<given-names>G. M.</given-names>
<surname>Raj</surname>
</string-name>
</person-group> (<publisher-name>Springer Nature Singapore</publisher-name>, <year>2022</year>), <fpage>383</fpage>&#x02013;<lpage>389</lpage>.</mixed-citation></ref><ref id="hsr270849-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="hsr270849-cit-0006">
<string-name>
<given-names>L. R.</given-names>
<surname>Schiller</surname>
</string-name>, &#x0201c;<article-title>Antidiarrheal Drug Therapy</article-title>,&#x0201d; <source>Current Gastroenterology Reports</source>
<volume>19</volume>, no. <issue>5</issue> (<year>2017</year>): <fpage>18</fpage>.<pub-id pub-id-type="pmid">28397130</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0007"><label>7</label><mixed-citation publication-type="book" id="hsr270849-cit-0007">
<string-name>
<given-names>V. J.</given-names>
<surname>Kumpf</surname>
</string-name>, &#x0201c;<part-title>Chapter 12&#x02014;Antidiarrheals, Antisecretory Agents, Pancreatic Enzymes</part-title>.&#x0201d; In <source>Adult Short Bowel Syndrome</source>, eds. <person-group person-group-type="editor">
<string-name>
<given-names>M. L.</given-names>
<surname>Corrigan</surname>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<given-names>K.</given-names>
<surname>Roberts</surname>
</string-name>
</person-group>, and <person-group person-group-type="editor">
<string-name>
<given-names>E.</given-names>
<surname>Steiger</surname>
</string-name>
</person-group> (<publisher-name>Academic Press</publisher-name>, <year>2019</year>), <fpage>165</fpage>&#x02013;<lpage>176</lpage>.</mixed-citation></ref><ref id="hsr270849-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="hsr270849-cit-0008">
<string-name>
<given-names>K. J.</given-names>
<surname>Lee</surname>
</string-name>, &#x0201c;<article-title>Pharmacologic Agents for Chronic Diarrhea</article-title>,&#x0201d; <source>Intestinal Research</source>
<volume>13</volume>, no. <issue>4</issue> (<year>2015</year>): <fpage>306</fpage>&#x02013;<lpage>312</lpage>.<pub-id pub-id-type="pmid">26576135</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="hsr270849-cit-0009">
<string-name>
<given-names>D.</given-names>
<surname>Gupta</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Pandey</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Verma</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>M. Pujari</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Shukla</surname>
</string-name>, &#x0201c;<article-title>Medical Developments on Antidiarrheal Treatment</article-title>,&#x0201d; <source>New Advances in Medicine and Medical Science</source>
<volume>3</volume> (<year>2023</year>): <fpage>1</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="hsr270849-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="hsr270849-cit-0010">
<string-name>
<given-names>R. M.</given-names>
<surname>McQuade</surname>
</string-name>, <string-name>
<given-names>J. C.</given-names>
<surname>Bornstein</surname>
</string-name>, and <string-name>
<given-names>K.</given-names>
<surname>Nurgali</surname>
</string-name>, &#x0201c;<article-title>Anti&#x02010;Colorectal Cancer Chemotherapy&#x02010;Induced Diarrhoea: Current Treatments and Side&#x02010;Effects</article-title>,&#x0201d; <source>International Journal of Clinical Medicine</source>
<volume>05</volume> (<year>2014</year>): <fpage>393</fpage>&#x02013;<lpage>406</lpage>.</mixed-citation></ref><ref id="hsr270849-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="hsr270849-cit-0011">
<string-name>
<given-names>L. R.</given-names>
<surname>Schiller</surname>
</string-name>, &#x0201c;<article-title>Review Article: Anti&#x02010;Diarrheal Pharmacology and Therapeutics</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>9</volume>, no. <issue>2</issue> (<year>1995</year>): <fpage>86</fpage>&#x02013;<lpage>106</lpage>.</mixed-citation></ref><ref id="hsr270849-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="hsr270849-cit-0012">
<string-name>
<given-names>H. H.</given-names>
<surname>Wang</surname>
</string-name>, &#x0201c;<article-title>A Blind, Randomized Comparison of Racecadotril and Loperamide for Stopping Acute Diarrhea in Adults</article-title>,&#x0201d; <source>World Journal of Gastroenterology</source>
<volume>11</volume>, no. <issue>10</issue> (<year>2005</year>): <fpage>1540</fpage>&#x02013;<lpage>1543</lpage>.<pub-id pub-id-type="pmid">15770734</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="hsr270849-cit-0013">
<string-name>
<given-names>L.</given-names>
<surname>Gallelli</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Colosimo</surname>
</string-name>, <string-name>
<given-names>G. A.</given-names>
<surname>Tolotta</surname>
</string-name>, et al., &#x0201c;<article-title>Prospective Randomized Double&#x02010;Blind Trial of Racecadotril Compared With Loperamide in Elderly People With Gastroenteritis Living in Nursing Homes</article-title>,&#x0201d; <source>European Journal of Clinical Pharmacology</source>
<volume>66</volume>, no. <issue>2</issue> (<year>2010</year>): <fpage>137</fpage>&#x02013;<lpage>144</lpage>.<pub-id pub-id-type="pmid">19902197</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="hsr270849-cit-0014">
<string-name>
<given-names>J.</given-names>
<surname>Roge</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Baumer</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Berard</surname>
</string-name>, <string-name>
<given-names>J. C.</given-names>
<surname>Schwartz</surname>
</string-name>, and <string-name>
<given-names>J. M.</given-names>
<surname>Lecomte</surname>
</string-name>, &#x0201c;<article-title>The Enkephalinase Inhibitor, Acetorphan, in Acute Diarrhoea: A Double&#x02010;Blind, Controlled Clinical Trial Versus Loperamide</article-title>,&#x0201d; <source>Scandinavian Journal of Gastroenterology</source>
<volume>28</volume>, no. <issue>4</issue> (<year>1993</year>): <fpage>352</fpage>&#x02013;<lpage>354</lpage>.<pub-id pub-id-type="pmid">8488368</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="hsr270849-cit-0015">
<string-name>
<given-names>J. M.</given-names>
<surname>Vetel</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Berard</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Fretault</surname>
</string-name>, and <string-name>
<given-names>J. M.</given-names>
<surname>Lecomte</surname>
</string-name>, &#x0201c;<article-title>Comparison of Racecadotril and Loperamide in Adults With Acute Diarrhea</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>13</volume>, no. <issue>s6</issue> (<year>1999</year>): <fpage>21</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">10646048</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="hsr270849-cit-0016">
<string-name>
<given-names>D.</given-names>
<surname>Prado</surname>
</string-name>, &#x0201c;<article-title>A Multinational Comparison of Racecadotril and Loperamide in the Treatment of Acute Watery Diarrhoea in Adults</article-title>,&#x0201d; <source>Scandinavian Journal of Gastroenterology</source>
<volume>37</volume>, no. <issue>6</issue> (<year>2002</year>): <fpage>656</fpage>&#x02013;<lpage>661</lpage>.<pub-id pub-id-type="pmid">12126242</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="hsr270849-cit-0017">
<string-name>
<given-names>M. P.</given-names>
<surname>Primi</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Bueno</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Baumer</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Berard</surname>
</string-name>, and <string-name>
<given-names>J. M.</given-names>
<surname>Lecomte</surname>
</string-name>, &#x0201c;<article-title>Racecadotril Demonstrates Intestinal Antisecretory Activity In Vivo</article-title>,&#x0201d; supplement, <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>13</volume>, no. <issue>S6</issue> (<year>1999</year>): <fpage>S3</fpage>&#x02013;<lpage>S7</lpage>.</mixed-citation></ref><ref id="hsr270849-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="hsr270849-cit-0018">
<string-name>
<given-names>T.</given-names>
<surname>Mellstrand</surname>
</string-name>, &#x0201c;<article-title>Loperamide&#x02014;An Opiate Receptor Agonist With Gastrointestinal Motility Effects</article-title>,&#x0201d; <source>Scandinavian Journal of Gastroenterology</source>
<volume>22</volume> (<year>1987</year>): <fpage>65</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">3563412</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="hsr270849-cit-0019">
<string-name>
<given-names>J. W.</given-names>
<surname>Brown</surname>
</string-name>, &#x0201c;<article-title>Toxic Megacolon Associated With Loperamide Therapy</article-title>,&#x0201d; <source>JAMA: Journal of the American Medical Association</source>
<volume>241</volume>, no. <issue>5</issue> (<year>1979</year>): <fpage>501</fpage>&#x02013;<lpage>502</lpage>.<pub-id pub-id-type="pmid">759668</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="hsr270849-cit-0020">
<string-name>
<given-names>P.</given-names>
<surname>Baumer</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Danquechin Dorval</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Bertrand</surname>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Vetel</surname>
</string-name>, <string-name>
<given-names>J. C.</given-names>
<surname>Schwartz</surname>
</string-name>, and <string-name>
<given-names>J. M.</given-names>
<surname>Lecomte</surname>
</string-name>, &#x0201c;<article-title>Effects of Acetorphan, an Enkephalinase Inhibitor, on Experimental and Acute Diarrhoea</article-title>,&#x0201d; <source>Gut</source>
<volume>33</volume>, no. <issue>6</issue> (<year>1992</year>): <fpage>753</fpage>&#x02013;<lpage>758</lpage>.<pub-id pub-id-type="pmid">1624154</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="hsr270849-cit-0021">
<string-name>
<given-names>Y.</given-names>
<surname>Liang</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zeng</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Gordon</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Wen</surname>
</string-name>, &#x0201c;<article-title>Racecadotril for Acute Diarrhea in Children</article-title>,&#x0201d; <source>Cochrane Database of Systematic Reviews</source>
<volume>12</volume>, no. <issue>12</issue> (<year>2019</year>): <elocation-id>Cd009359</elocation-id>.<pub-id pub-id-type="pmid">31858591</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="hsr270849-cit-0022">
<string-name>
<given-names>J. P.</given-names>
<surname>C&#x000e9;zard</surname>
</string-name>, <string-name>
<given-names>J. F.</given-names>
<surname>Duhamel</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Meyer</surname>
</string-name>, et al., &#x0201c;<article-title>Efficacy and Tolerability of Racecadotril in Acute Diarrhea in Children</article-title>,&#x0201d; <source>Gastroenterology</source>
<volume>120</volume>, no. <issue>4</issue> (<year>2001</year>): <fpage>799</fpage>&#x02013;<lpage>805</lpage>.<pub-id pub-id-type="pmid">11231932</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="hsr270849-cit-0023">
<string-name>
<given-names>H.</given-names>
<surname>Hamza</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Ben Khalifa</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Baumer</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Berard</surname>
</string-name>, and <string-name>
<given-names>J. M.</given-names>
<surname>Lecomte</surname>
</string-name>, &#x0201c;<article-title>Racecadotril Versus Placebo in the Treatment of Acute Diarrhea in Adults</article-title>,&#x0201d; <source>Alimentary Pharmacology &#x00026; Therapeutics</source>
<volume>13</volume>, no. <issue>s6</issue> (<year>1999</year>): <fpage>15</fpage>&#x02013;<lpage>19</lpage>.</mixed-citation></ref><ref id="hsr270849-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="hsr270849-cit-0024">
<string-name>
<given-names>M.</given-names>
<surname>Eberlin</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Mueck</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>D&#x000e4;britz</surname>
</string-name>, &#x0201c;<article-title>Racecadotril in the Treatment of Acute Diarrhea in Children: A Systematic, Comprehensive Review and Meta&#x02010;Analysis of Randomized Controlled Trials</article-title>,&#x0201d; <source>BMC Pediatrics</source>
<volume>18</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>124</fpage>.<pub-id pub-id-type="pmid">29614995</pub-id>
</mixed-citation></ref><ref id="hsr270849-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="hsr270849-cit-0025">
<string-name>
<given-names>R. F.</given-names>
<surname>Bavurhe</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Rusho</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Balume</surname>
</string-name>, et al., &#x0201c;<article-title>Cross&#x02010;Sectional Study Exploring the Prevalence and Clinical Manifestations of Acute Diarrhea Among Under&#x02010;5 Children in Primary Care Hospital in Democratic Republic of the Congo</article-title>,&#x0201d; <source>Annals of Medicine &#x00026; Surgery</source>
<volume>86</volume>, no. <issue>12</issue> (<year>2024</year>): <fpage>6983</fpage>&#x02013;<lpage>6988</lpage>, <pub-id pub-id-type="doi">10.1097/MS9.0000000000002618</pub-id>.<pub-id pub-id-type="pmid">39649910</pub-id>
</mixed-citation></ref></ref-list></back></article>